EU Pharma: ADA Conf Wrap: What matters for NOVOB, ROP, AZN, ZEAL, + key US updates - competition continues to heat up, differentiation vs. LLY still needed in many areas

Research evidence excerpt

EU Pharma: ADA Conf Wrap: What matters for NOVOB, ROP, AZN, ZEAL, + key US updates - competition continues to heat up, differentiation vs. LLY still needed in many areas

arances and trading securities held by a research analyst’s account.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment

or reimbursement by any covered company of their travel expenses for such visits.

Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis,

quantitative analysis, and trade ideas. Recommendations contained in one type of Barclays Research may differ from those contained in other types of

Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://

publicresearch.barclays.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://

publicresearch.barclays.com/S/CM.htm.

Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last

available closing price at the time of publication.

Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit

holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

Disclosure(s) regarding Information Sources

Bloomberg® is a trademark and service mark of Bloomberg Finance L.P.